Loading...
Symbols:
Loading...
Symbols:
Nabi Biopharmaceuticals Continues Clinical Development of StaphVax (NABI)
March 24, 2006
| about stocks:
NABI
Last November, Nabi Biopharmaceuticals (ticker: NABI) announced that the confirmatory Phase 3 study of StaphVax failed to meet its primary endpoint. Because the results were contrary to what the company predicted would occur, they formed an outside advisory panel to determine what caused the “unexpected results.
Related Articles
|
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
More by BioBlogger
Articles on related themes
Biotech Diagnosis
Biotech Equipment
Biotech Research